Clinical potential of treatment with semaglutide in type 2 diabetes patients
Glucagon-like receptor agonists (GLP-1RAs) are included in current national and international guidelines as second-line treatment especially in patients with type 2 diabetes and concomitant cardiovascular disease (CVD). First-generation GLP-1RAs were two- or once-daily injectables, but longeracting...
Saved in:
Main Author: | Michael E Røder (Author) |
---|---|
Format: | Book |
Published: |
BioExcel Publishing Ltd,
2019-12-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Semaglutide in the Treatment of Diabetes and Associated Obesity
by: Rafal Makuch, et al.
Published: (2024) -
Semaglutide versus Tirzepatide - comparison of both drugs in treatment of diabetes type 2 and weight reduction
by: Arkadiusz Staroń, et al.
Published: (2024) -
Profile of semaglutide in the management of type 2 diabetes: design, development, and place in therapy
by: Gomez-Peralta F, et al.
Published: (2019) -
Type 2 diabetes mellitus pharmacological remission with dapagliflozin plus oral semaglutide
by: Maria Elena Lunati, et al.
Published: (2024) -
Cost consequence analysis of adding semaglutide to treatment regimen for patients with Type II diabetes in Saudi Arabia
by: Yazed AlRuthia, et al.
Published: (2024)